|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lp-PLA2 is a novel inflammation marker in cardiovascular disease.
|
30043502 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA<sub>2</sub>) is a novel inflammatory biomarker, which is useful as an adjunct identification tool for cardiovascular disease.
|
30414434 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study is the first to confirm that AAP administration, especially clozapine and olanzapine, could increase Lp-PLA2 levels and CVD risk, independent of drug-induced weight gain in schizophrenia.
|
29938908 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review.
|
28502488 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulatory macrophage-derived factor that increases with obesity and leads to a higher risk of cardiovascular disease (CVD).
|
29427237 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There was no interaction or modifier effect of the Lp-PLA2 inhibitor darapladib assignment on the relationship between rs10846744 and major CVD events in either STABILITY or SOLID-TIMI 52.
|
30289950 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lipoprotein-associated phospholipase A2 assessment might be used for MI and CVD death risk prediction.
|
28429599 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA<sub>2</sub>), an enzyme associated with inflammation, is used as a biomarker for cardiovascular disease risk.
|
29321128 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The increased plasma PAF-AH and apoB-PAF-AH activities in patients with H allele of R92H are related to the R92 → H variation, changes in plasma lipoprotein levels, insulin resistance, aging, and gaining weight and thus may be involved in the pathogenesis of PCOS and the increased risks of future cardiovascular diseases.
|
28320416 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In a fully adjusted model, greater LpPLA2 activity was independently associated with incident CVD (HR 1.35, 1.09-1.68 for highest vs. lowest quintile), which was mainly explained by its association with CHD, and was also associated with all-cause mortality (HR 1.65, 1.38-1.98).
|
26117401 |
2015 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ω3-polyunsaturated fatty acids (ω3-PUFAs) have beneficial effects on cardiovascular function, and lipoprotein-associated phospholipase A2 (Lp-PLA2 ) is associated with the risk of cardiovascular disease.
|
26018800 |
2015 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations led to the hypothesis that Lp-PLA(2) activity and/or mass levels could be used as biomarkers of cardiovascular disease and that inhibition of the activity could offer an attractive therapeutic strategy.
|
22665167 |
2012 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an independent risk factor of cardiovascular disease and a target of treatment.
|
21262507 |
2011 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an emerging risk factor and therapeutic target for cardiovascular disease.
|
20442857 |
2010 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The human PLA2G7 gene encodes lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), an emerging risk factor for cardiovascular diseases.
|
19034521 |
2009 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher circulating Lp-PLA(2) predicts cardiovascular disease risk, but sources of inter-individual variability are incompletely understood.
|
19135199 |
2009 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Irrespective of the significant association between some variants with plasma LpPLA2 activity, it is still unclear whether these polymorphisms or haplotypes are associated with the risk and outcome of cardiovascular disease in Caucasians.
|
18983494 |
2009 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.
|
18204052 |
2008 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These observations should provide useful information for future clinical and epidemiological evaluations of the Lp-PLA2 activity in cardiovascular diseases in Japanese.
|
17587752 |
2007 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lp-PLA(2) activity was lower in CVD patients taking a lipid-lowering drug (31%), those not taking a lipid-lowering drug (26%), and control subjects (23%) with the V/F genotype, compared with those with the V/V genotype.
|
16787988 |
2006 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
|
15713711 |
2005 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease.
|
12865731 |
2003 |